circulating tumor DNA
Natera Builds Data Backing Serial ctDNA Changes to Aid CRC Patient Management, Treatment Decisions
Premium
The company believes its findings are the first to show that quantifying ctDNA changes can stratify high-risk colorectal cancer patients into better and worse prognostic groups.
Elicio Therapeutics Begins Phase I/II Vaccine Trial in KRAS-Driven Cancers
The study will enroll patients with solid tumors with KRAS mutations and who have circulating tumor DNA after surgery or chemotherapy.
Guardant Health Begins Study of Reveal Liquid Biopsy Test to Predict Cancer Recurrence
The company hopes the study will allow it to expand the use of its ctDNA test to monitor disease recurrence in patients with tumors other than colorectal cancer.
Personal Genome Diagnostics, Cleveland Clinic Join Forces to Advance Liquid Biopsy
Leaders from collaborating Cleveland Clinic institutes will work with PGDx to optimize its ctDNA test reporting and adapt its technology for new oncology applications.
Cell-Free DNA Can Help Predict Pathological Complete Response, Gauge Minimal Residual Disease
A suite of new studies examined how liquid biopsies could personalize treatment strategies in a range of cancer types.